News & Updates
Filter by Specialty:

Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
byRoshini Claire Anthony
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
Tofacitinib on par with TNFi in rheumatoid arthritis
19 May 2022
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
Tofacitinib on par with TNFi in rheumatoid arthritis
19 May 2022
Multi-metal exposure ups diabetes mellitus risk
19 May 2022
Exposure to different metals, particularly cadmium, iron, zinc, copper, and lead, appears to aggravate the risks of impaired fasting glucose (IFG) and diabetes mellitus, reports a recent China study.